aTyr Pharma (NASDAQ:ATYR - Get Free Report) had its price objective increased by equities research analysts at Wells Fargo & Company from $17.00 to $25.00 in a report released on Friday,Benzinga reports. The brokerage currently has an "overweight" rating on the stock. Wells Fargo & Company's price objective points to a potential upside of 383.56% from the company's previous close.
Separately, HC Wainwright reiterated a "buy" rating and set a $35.00 price objective on shares of aTyr Pharma in a research note on Wednesday, June 4th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $20.20.
Check Out Our Latest Research Report on aTyr Pharma
aTyr Pharma Stock Performance
Shares of ATYR stock opened at $5.17 on Friday. The company's fifty day moving average price is $3.95 and its 200-day moving average price is $3.65. The stock has a market cap of $460.13 million, a PE ratio of -6.38 and a beta of 0.88. The company has a current ratio of 7.79, a quick ratio of 7.79 and a debt-to-equity ratio of 0.01. aTyr Pharma has a 12 month low of $1.42 and a 12 month high of $5.98.
aTyr Pharma (NASDAQ:ATYR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.02. On average, equities analysts expect that aTyr Pharma will post -0.91 EPS for the current fiscal year.
Institutional Trading of aTyr Pharma
A number of institutional investors and hedge funds have recently modified their holdings of ATYR. Federated Hermes Inc. bought a new position in shares of aTyr Pharma during the fourth quarter valued at $53,093,000. Point72 Asset Management L.P. bought a new position in aTyr Pharma during the 4th quarter valued at about $17,677,000. Octagon Capital Advisors LP boosted its holdings in shares of aTyr Pharma by 294.7% during the 1st quarter. Octagon Capital Advisors LP now owns 3,552,000 shares of the company's stock valued at $10,727,000 after acquiring an additional 2,652,000 shares during the last quarter. Tikvah Management LLC bought a new position in aTyr Pharma during the fourth quarter valued at approximately $8,908,000. Finally, Woodline Partners LP purchased a new stake in aTyr Pharma in the fourth quarter worth approximately $6,092,000. Institutional investors own 61.72% of the company's stock.
About aTyr Pharma
(
Get Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider aTyr Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and aTyr Pharma wasn't on the list.
While aTyr Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
